<DOC>
	<DOCNO>NCT01040494</DOCNO>
	<brief_summary>Aliskiren potent direct renin inhibitor recently show favorable neurohumoral effect patient heart failure ( HF ) Objective：To study effect add-on aliskiren treatment patient HF component arterial load , central aorta peripheral arteriole biomarkers Methods：Patients NYHA Class II IV HF , treat angiotensin-converting enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) beta-blocker randomize 6 month treatment placebo aliskiren ( 150mg per day ) treatment . Components arterial load , central aorta peripheral arteriole well wide-range biomarkers , include inflammatory biomarkers , N-terminal pro-B type natriuretic peptide , arterial remodel marker ( procollagen , matrix metalloproteinase ) measure , 2 month 6 month treatment . What New Innovative study ? The importance central hemodynamics biomarker change patient HF show observation study . This first randomize control trial examines comprehensively effect direct rennin inhibitor central hemodynamics biomarkers HF patient receive standard heart failure therapy .</brief_summary>
	<brief_title>Add-on Aliskiren Treatment Patients With Chronic Congestive Heart Failure</brief_title>
	<detailed_description>Introduction : Aliskiren potent direct renin inhibitor recently show favorable neurohumoral effect patient heart failure ( HF ) Objective：To study effect add-on aliskiren treatment patient HF component arterial load , central aorta peripheral arteriole biomarkers Methods：Patients NYHA Class II IV HF , treat angiotensin-converting enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) beta-blocker randomize 6 month treatment placebo aliskiren ( 150mg per day ) treatment . Components arterial load , central aorta peripheral arteriole well wide-range biomarkers , include inflammatory biomarkers , N-terminal pro-B type natriuretic peptide , arterial remodel marker ( procollagen , matrix metalloproteinase ) measure , 2 month 6 month treatment . What New Innovative study ? The importance central hemodynamics biomarker change patient HF show observation study . This first randomize control trial examines comprehensively effect direct rennin inhibitor central hemodynamics biomarkers HF patient receive standard heart failure therapy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Outpatients ≥ 18 year age , male female . Female patient must either postmenopausal one year , surgically sterile , use effective contraceptive method oral contraceptive , barrier method spermicide intrauterine device . 2 . Patients diagnosis chronic heart failure ( NYHA Class IIIV ) reduce systolic function : LVEF ≤ 45 % Visit 1 ( local measurement , measure within past 6 month assess echocardiogram , MUGA , CT scan , MRI ventricular angiography ) . 3 . Patients must stable dose either ACE inhibitor ARB least 4 week prior Visit 1 . 4 . Patients must treat beta blocker , unless contraindicate tolerated , stable dose least 4 week prior Visit 1 . 5 . Patients document sinus rhythm Visit 1 . 1 . History hypersensitivity study drug . 2 . Patients require treatment ACEI ARB . 3 . Current acute decompensated HF ( exacerbation chronic HF manifest sign &amp; symptom may require IV therapy ) . 4 . Symptomatic hypotension and/or le 100 mmHg time screen less 90 mmHg time randomization . 5. eGFR &lt; 30 ml/min/1.73m2 measure MDRD formula Visit 1 ( screen ) , &gt; 25 % decrease 14 day active runin period . 6 . Serum potassium &gt; 5.0 mmol/L screening ( Visit 1 ) . 7 . Acute coronary syndrome , stroke , transient ischemic attack , cardiac , carotid major vascular surgery , percutaneous coronary intervention ( PCI ) carotid angioplasty , within past 3 month prior visit 1 . 8 . Coronary carotid artery disease likely require surgical percutaneous intervention within 6 month Visit 1 . 9 . Patients active unstable bronchospasm asthma ( patient must stable regimen respiratory medication 1 month prior Visit 1 ) . 10 . Right heart failure due severe pulmonary disease . 11 . Diagnosis peripartum chemotherapy induce cardiomyopathy within 12 month prior visit 1 . 12 . Patients history heart transplant transplant list leave ventricular assistance device ( LVAD device ) . 13 . Documented ventricular arrhythmia syncopal episode within past 3 month , prior visit 1 , untreated . 14 . Symptomatic bradycardia second third degree heart block without pacemaker . 15 . Implantation CRT ( cardiac resynchronization therapy ) device within prior 3 month visit 1 intent implant CRT device . 16 . Presence hemodynamically significant mitral and/or aortic valve disease , except mitral regurgitation secondary leave ventricular dilatation . 17 . Presence hemodynamically significant obstructive lesion leave ventricular outflow tract , include aortic subaortic stenosis . 18 . Severe primary pulmonary , renal hepatic disease . 19 . Presence disease life expectancy &lt; 1 year . 20 . Chronic longterm requirement NSAIDs ( high dose ) COX2 inhibitor , exception aspirin dos use CV prophylaxis ( ≤325 mg o.d. ) . 21 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion study drug 22 . Subjects breast feeding , get pregnant pregnant within 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Congestive heart failure</keyword>
	<keyword>Central hemodynamics</keyword>
</DOC>